313535-84-1

Basic information

• Product Name: Methyl 4-hydroxyquinazoline-7-carboxylate
• Synonyms: Methyl 4-hydroxyquinazoline-7-carboxylate;Methyl 4-hydroxyquinazoline-7-carboxylate 97%;4-Hydroxy-7-(methoxycarbonyl)quinazoline;7-Quinazolinecarboxylicacid, 3,4-dihydro-4-oxo-, Methyl ester;4-keto-1H-quinazoline-7-carboxylic acid methyl ester;4-oxo-1H-quinazoline-7-carboxylic acid methyl ester;methyl 4-oxo-1H-quinazoline-7-carboxylate;MO 08192
• CAS NO: 313535-84-1
• Molecular Formula: C₁₀H₈N₂O₃
• Molecular Weight: 204.18212
• Mol File: 313535-84-1.mol

Chemical Properties

• Melting Point: 252.5-254.5
• Boiling Point: 378.6 °C at 760 mmHg
• Flash Point: 182.8 °C
• Appearance: /
• Density: 1.39 g/cm³
• Vapor Pressure: 6.21E-06mmHg at 25°C
• Refractive Index: 1.638
• PKA: 0.39±0.20(Predicted)
• CAS DataBase Reference: Methyl 4-hydroxyquinazoline-7-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-hydroxyquinazoline-7-carboxylate(313535-84-1)
• EPA Substance Registry System: Methyl 4-hydroxyquinazoline-7-carboxylate(313535-84-1)

Safety Data

• Statements: 20/22
• Safety Statements: 36/37
• Hazardous Substances Data: 313535-84-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-hydroxyquinazoline-7-carboxylate is utilized as a precursor in the synthesis of pharmaceutical compounds due to its quinazoline core, which is a common structural element in many bioactive molecules. Its potential antibacterial, antifungal, and antitumor properties make it a valuable building block for developing new drugs targeting a range of diseases and conditions.
Used in Organic Synthesis:
In the field of organic synthesis, Methyl 4-hydroxyquinazoline-7-carboxylate serves as a key intermediate for creating more complex molecules. Its functional groups allow for further chemical reactions, facilitating the construction of advanced organic compounds for use in pharmaceuticals, agrochemicals, or as research tools.
Used in Research and Development:
Methyl 4-hydroxyquinazoline-7-carboxylate is also employed in research settings to explore its biological activities and potential therapeutic effects. Scientists use Methyl 4-hydroxyquinazoline-7-carboxylate to investigate its interactions with biological targets, such as enzymes or receptors, which can provide insights into its mechanism of action and guide the design of more effective drugs.

InChI:InChI=1/C10H8N2O3/c1-15-10(14)6-2-3-7-8(4-6)11-5-12-9(7)13/h2-5H,1H3,(H,11,12,13)

Upstream product

• 85743-02-8 2-amino-benzene-1,4-dicarboxylic acid,4-methyl ester 
• 77287-34-4 formamide 
• 5372-81-6 dimethyl aminoterephthalate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 67-56-1 methanol 
• 202197-73-7 4-oxo-3,4-dihydroquinazoline-7-carboxylic acid 

Relevant articles and documents

Photoinduced homolytic decarboxylative acylation/cyclization of unactivated alkenes with α-keto acid under external oxidant and photocatalyst free conditions: access to quinazolinone derivatives

A novel and green strategy for the synthesis of acylated quinazolinone derivativesviaphoto-induced decarboxylative cascade radical acylation/cyclization of quinazolinone bearing unactivated alkenes has been developed. The protocol provides a novel route to access acyl radicals from α-keto acids through a self-catalyzed energy transfer process. Most importantly, the reaction proceeded smoothly without any external photocatalyst, additive or oxidant, and could be easily scaled-up in flow conditions with sunlight irradiation.

IDENTIFICATION AND USE OF ERK5 INHIBITORS

The present invention covers heterocyclic compounds of general formula (I) in which T, U, Y, Z, R1 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer disorders, as a sole agent or in combination with other active ingredients.

Addressing the Glycine-Rich Loop of Protein Kinases by a Multi-Facetted Interaction Network: Inhibition of PKA and a PKB Mimic

Protein kinases continue to be hot targets in drug discovery research, as they are involved in many essential cellular processes and their deregulation can lead to a variety of diseases. A series of 32 enantiomerically pure inhibitors was synthesized and tested towards protein kinase A (PKA) and protein kinase B mimic PKAB3 (PKA triple mutant). The ligands bind to the hinge region, ribose pocket, and glycine-rich loop at the ATP site. Biological assays showed high potency against PKA, with Ki values in the low nanomolar range. The investigation demonstrates the significance of targeting the often neglected glycine-rich loop for gaining high binding potency. X-ray co-crystal structures revealed a multi-facetted network of ligand-loop interactions for the tightest binders, involving orthogonal dipolar contacts, sulfur and other dispersive contacts, amide-π stacking, and H-bonding to organofluorine, besides efficient water replacement. The network was analyzed in a computational approach.

Sulfonamide compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R 1 --SO 2 NHCO--A--R 2 (I)wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.